ETFs Holding ACOR »    ACOR Historical Stock Prices »
ACOR News Video: Wed, Jun 21, 2017, 10:31 AM — Wednesday 6/21 Insider Buying Report: ACOR, SBBX

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies for neurological disorders. Co.'s therapies include: Ampyra, an extended release tablet formulation of dalfampridine for the treatment of multiple sclerosis (MS); Zanaflex Capsules and tablets, a short-acting drugs for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Co. has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. Co. has three clinical-stage programs in Parkinson's disease, including CVT-301, as well as its tozadenant and SYN120 programs. Self directed investors in Acorda Therapeutics Inc will be interested in keeping up with all Acorda Therapeutics Inc news they can find, both ACOR news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ACOR. At RediNews, we simplify this task by presenting both ACOR news releases originating from Acorda Therapeutics Inc itself, and ACOR news from a variety of media outlets. Visitors can browse this news online and through our ACOR RSS news feed.


ACOR News — Articles, Videos, & Press Releases

First Week of October 19th Options Trading For Acorda Therapeutics (ACOR)
3 hours, 18 minutes ago — Stock Options Channel
FDA Accepts Acorda's NDA for Parkinson's Disease Candidate
Wednesday, February 21, 2018, 8:38 AM — Zacks
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
Friday, February 16, 2018, 9:16 AM — Zacks
Alkermes Submits NDA for Depression Candidate to the FDA
Thursday, February 1, 2018, 8:08 AM — Zacks
Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%
Monday, January 22, 2018, 7:43 AM — Zacks
Notable Thursday Option Activity: ACOR, VHC, TREE
Thursday, January 18, 2018, 3:16 PM — Stock Options Channel
Acorda's Shares Down on Disappointing Ampyra View for 2018
Tuesday, January 9, 2018, 3:35 PM — Zacks
Notable Monday Option Activity: ACOR, MODN, SCHN
Monday, January 8, 2018, 3:28 PM — Stock Options Channel
Sum Up The Parts: PBE Could Be Worth $55
Friday, January 5, 2018, 9:11 AM — ETF Channel
ACOR Crosses Above Key Moving Average Level
Wednesday, December 13, 2017, 11:41 AM — Market News Video
Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija
Friday, December 8, 2017, 2:41 PM — Zacks
Parkinson's Space in Focus as Acorda Stops Tozadenant Trial
Wednesday, November 22, 2017, 9:57 AM — Zacks
Acorda Stock Up Despite Phase III Trial on Tozadenant Stops
Tuesday, November 21, 2017, 3:29 PM — Zacks
Acorda Reports Death in Parkinson's Trials, Stock Down 40%
Thursday, November 16, 2017, 11:13 AM — Zacks
Interesting ACOR Put Options For November 17th
Thursday, November 16, 2017, 10:33 AM — Stock Options Channel
Implied PBE Analyst Target Price: $57
Thursday, November 16, 2017, 9:27 AM — ETF Channel
Notable Wednesday Option Activity: WMT, ACOR, GNC
Wednesday, November 15, 2017, 3:26 PM — Stock Options Channel
Oversold Conditions For Acorda Therapeutics (ACOR)
Wednesday, November 15, 2017, 11:57 AM — Dividend Channel
First Week of December 15th Options Trading For Acorda Therapeutics (ACOR)
Thursday, November 2, 2017, 10:33 AM — Stock Options Channel
Short Interest In Acorda Therapeutics Drops 12.7%
Wednesday, October 25, 2017, 1:48 PM — Market News Video
Commit To Purchase Acorda Therapeutics At $17, Earn 15.6% Annualized Using Options
Monday, October 23, 2017, 11:46 AM — Stock Options Channel
Acorda Therapeutics Reaches Analyst Target Price
Monday, October 23, 2017, 10:15 AM — ETF Channel
Acorda Therapeutics Stock Sees Short Interest Move 12.6% Higher
Wednesday, September 27, 2017, 1:38 PM — Market News Video
ACOR Crosses Above Average Analyst Target
Wednesday, September 20, 2017, 10:25 AM — ETF Channel
Analysts Expect SLY To Hit $135
Thursday, August 31, 2017, 8:34 AM — ETF Channel
Analysts Forecast 13% Upside For PBE
Monday, July 31, 2017, 10:03 AM — ETF Channel
September 15th Options Now Available For Acorda Therapeutics (ACOR)
Monday, July 24, 2017, 11:39 AM — Stock Options Channel
Short Interest Makes 16% Move For ACOR
Thursday, July 13, 2017, 1:48 PM — Market News Video
PBE's Underlying Holdings Imply 12% Gain Potential
Wednesday, June 28, 2017, 8:44 AM — ETF Channel
Top Buys by Top Brass: CEO Cohen's $339K Bet on ACOR
Wednesday, June 21, 2017, 10:31 AM — Dividend Channel
Oversold Conditions For Acorda Therapeutics (ACOR)
Thursday, May 25, 2017, 4:24 PM — Dividend Channel
Look Under The Hood: XBI Has 31% Upside
Monday, May 15, 2017, 10:32 AM — ETF Channel
Commit To Purchase Acorda Therapeutics At $13, Earn 14.2% Annualized Using Options
Tuesday, April 25, 2017, 11:45 AM — Stock Options Channel
Analysts Predict 10% Gains Ahead For IJS
Friday, April 14, 2017, 8:56 AM — ETF Channel
Acorda Therapeutics (ACOR) Shares Cross Below 200 DMA
Friday, March 31, 2017, 4:39 PM — Market News Video
Noteworthy Friday Option Activity: AMBA, ACOR, CC
Friday, March 31, 2017, 3:45 PM — Stock Options Channel
Implied PBE Analyst Target Price: $52
Tuesday, March 14, 2017, 9:20 AM — ETF Channel
Noteworthy Thursday Option Activity: EBIX, LOCO, ACOR
Thursday, March 9, 2017, 3:28 PM — Stock Options Channel
ACOR is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:


RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ACOR News | | Copyright © 2013 - 2018, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.